RxDoctor Payments Data

Gunjan Gandhi, MD

Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1952387912

Payments from drug & device makers

$809in general payments, 2019–2025

Across 34 payments — averaging $23.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$397
  • Abbott$171
  • Novo Nordisk$99
  • Corcept Therapeutics$88
  • Ultragenyx Pharmaceutical Inc.$30
  • Radius Health, Inc.$17
  • plus $7 from 1 others

What the payments were for

  • Food & beverage$77996%
  • Education$304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$809 in reported general payments places this provider in the 25th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$38,218
Medicare patients
208
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide124$152,801
TrulicityDulaglutide46$64,102
JardianceEmpagliflozin54$61,985
MounjaroTirzepatide20$24,176
JanuviaSitagliptin Phosphate20$21,456
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$15,037
Humalog Kwikpen U-100Insulin Lispro25$7,474
FarxigaDapagliflozin Propanediol11$7,331
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$7,209
Novolog FlexpenInsulin Aspart35$6,236
Testosterone19$5,899
SynthroidLevothyroxine Sodium65$5,836
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp12$4,565
Hydrocortisone51$3,057
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$2,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$99$152,801124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →